Narsoplimab Biosimilar - Research Grade

Human

MASP2

>1mg/ml

IgG4 - lambda2

CHO Cells

https://www.imgt.org/mAb-DB/

ICH3002

O00187

10747

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of narsoplimab, supplied for research use only and not for human or veterinary use. Narsoplimab is a fully human antibody directed against mannan-binding lectin-associated serine protease-2 (MASP-2), the effector enzyme of the lectin pathway of complement. The research-grade analog is built around this MASP-2 target and reproduces the originator's binding specificity, making it useful as a positive control, a reference or benchmarking reagent, and a tool for interrogating lectin-pathway biology in vitro. Typical applications include lectin-pathway complement neutralization assays, target-engagement and binding studies, ELISA and surface-based affinity work, and preclinical model characterization. It is offered at low endotoxin (research grade less than 1 EU/mg; ultra-low less than 0.5 EU/mg) and in bulk milligram-to-gram quantities suitable for assay development and scale-up. Because it is a laboratory reagent rather than the clinical drug, it is intended for functional and mechanistic experiments, not for therapeutic administration. Isotype is human IgG4, lambda light chain. MASP-2 (mannan-binding lectin-associated serine protease-2), encoded by MASP1's paralog gene MASP2 (UniProt O00187), is the key effector protease of the lectin pathway of complement activation. It circulates in complex with pattern-recognition molecules such as mannose-binding lectin (MBL), ficolins, and collectins. When these recognition molecules engage carbohydrate or acetylated patterns on microbial or damaged-cell surfaces, associated MASP-2 becomes activated and cleaves complement components C4 and C2 to form the C3 convertase (C4b2a). This drives downstream C3 activation, opsonization, inflammation, and membrane attack complex formation. MASP-2 thus initiates lectin-pathway-driven complement activity independently of the classical and alternative pathways, and is implicated in thrombotic microangiopathy and complement-mediated tissue injury, making it a focus of inhibitor research.

MBL-associated serine protease 2, Mannose-binding protein-associated serine protease 2, Mannan-binding lectin serine protease 2

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Narsoplimab (anti-MASP2) Biosimilar

Q: Is the Narsoplimab biosimilar available in bulk mg to gram quantities?

A: Yes — it is manufactured in scalable milligram to gram quantities for high-throughput and bulk in vivo experiments.

Q: Is this research-grade Narsoplimab biosimilar suitable for in vivo use?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Narsoplimab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Narsoplimab that binds MASP2; for research use only.